Cell-based therapy in ischemic stroke

David C. Hess, Cesar V. Borlongan

Research output: Contribution to journalReview articlepeer-review

101 Scopus citations


Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.

Original languageEnglish (US)
Pages (from-to)1193-1201
Number of pages9
JournalExpert Review of Neurotherapeutics
Issue number8
StatePublished - Aug 2008


  • Cell-based therapy
  • Marrow stromal cell
  • Mesenchymal stem cell
  • Phase I clinical trial
  • Restorative therapy
  • Stem cell

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Cell-based therapy in ischemic stroke'. Together they form a unique fingerprint.

Cite this